Infinity Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, INFI, Infinity Pharmaceuticals Inc, priceseries

Infinity Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.96
Close
0.94
High
0.98
Low
0.91
Previous Close
0.96
Daily Price Gain
-0.02
YTD High
2.41
YTD High Date
Jan 3, 2022
YTD Low
0.91
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.46
YTD Gain
-60.78%
52 Week High
3.89
52 Week High Date
Sep 2, 2021
52 Week Low
0.91
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-1.66
52 Week Gain
-63.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
2.07
Feb 17. 2017
2.38
13 Trading Days
14.91%
Link
LONG
Feb 27. 2017
2.45
Mar 6. 2017
2.69
5 Trading Days
10.00%
Link
LONG
Sep 1. 2017
1.05
Sep 19. 2017
1.21
11 Trading Days
14.97%
Link
LONG
Oct 4. 2017
1.31
Oct 9. 2017
1.38
3 Trading Days
5.34%
Link
LONG
Oct 11. 2017
1.67
Oct 18. 2017
2.19
5 Trading Days
30.97%
Link
LONG
Nov 8. 2017
2.52
Nov 10. 2017
2.67
2 Trading Days
6.15%
Link
LONG
Mar 1. 2018
1.92
Mar 20. 2018
2.41
13 Trading Days
25.39%
Link
LONG
Nov 18. 2019
0.99
Dec 10. 2019
1.22
15 Trading Days
23.12%
Link
LONG
Jan 9. 2020
1.19
Jan 13. 2020
1.25
2 Trading Days
5.46%
Link
LONG
Jul 31. 2020
0.89
Aug 24. 2020
1.18
16 Trading Days
33.24%
Link
LONG
Nov 6. 2020
1.13
Nov 25. 2020
1.85
13 Trading Days
63.94%
Link
LONG
Dec 8. 2020
2.77
Dec 9. 2020
2.95
1 Trading Days
6.50%
Link
LONG
Jan 7. 2021
2.39
Jan 27. 2021
3.39
13 Trading Days
41.80%
Link
LONG
May 26. 2021
3.08
Jun 15. 2021
3.26
13 Trading Days
5.86%
Link
LONG
Aug 4. 2021
2.66
Aug 18. 2021
2.99
10 Trading Days
12.33%
Link
LONG
Aug 20. 2021
3.02
Sep 10. 2021
3.60
14 Trading Days
19.18%
Link
Company Information
Stock Symbol
INFI
Exchange
NasdaqGS
Company URL
http://www.infi.com
Company Phone
6174531000
CEO
Adelene Q. Perkins
Headquarters
Massachusetts
Business Address
784 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001113148
About

Infinity Pharmaceuticals, Inc. is an innovative drug discovery and development company, which engages in discovering, developing and delivering medicines for difficult-to-treat diseases, developing novel small molecule drugs that target emerging disease pathways. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading